

# INDEX

- accelerated vesting, 41–42, 71–73, 93, 97
- accredited investors, 184, 186–187, 190, 193–194
- accruing dividends, 76, 78
- acquisition agreements, 260–270
- alternative dispute resolution (ADR), 135–136
- alternative minimum tax (AMT), 43, 45
- American Arbitration Association, 135
- angel investors, 21, 59, 62, 75
- annual report to SEC, 208–210, 216–217, 229–230, 233, 235
- antidilution provisions, 78–81
- antifraud statute Section 10(b), 182, 241
- Associated Press, 222
- attorneys
  - fees, 107
  - in mergers and acquisitions, 249, 253, 290–291
  - in preparing IPOs, 196–204
  - role in start-up phase, 1–4
  - in venture fund formation, 98
- audit committees, 204, 211, 228, 230–234
- authorized stock, 7, 20–21
- bankruptcy, 91, 94–95. *See also* liquidation
- baskets, 265–268
- Bayh-Dole Act (P.L. 96–517), 159, 167
- biological materials, 145–148, 153, 164–171
- biotechnology license agreements, 145–154
- Black-Scholes formula, 40
- blank check preferred stock, 20, 201
- blue sky laws, 186–187, 189, 192, 195
- board of directors
  - election of, 16–19
  - fiduciary duties, 28–30
  - first meeting of, 23
  - independence of, 204, 208, 228, 231–234, 240
  - and proxy statements, 228–229
  - venture capital and, 18, 67–69
- boilerplate provisions, 137, 203, 284, 286
- book-runner, 199
- bridge loans, 90–98
- bright-line test, 281–282
- business plans, 59–60, 70–71, 110, 112
- bylaws, 22, 24, 201, 213
- capital gains, 4, 31–34, 41–43, 45
- carried interest, 99, 102
- certificate of incorporation, 19–22
- cheap stock, 182, 203–205
- chief executive officer (CEO), 231–232, 234–235
- chief financial officer (CFO), 202, 204, 233, 235
- claw-back, 100
- cliff vesting, 14
- clinical trial agreements (CTAs), 152–155, 162–164
- closings, 262–263, 266, 268–269, 272–281, 286, 288, 291
- code of ethics, 211, 213, 234–235
- Collaborative Research and Development Agreement (CRADA), 161
- common stock
  - in IPOs, 195–196, 206, 208, 210, 214, 219, 229–230, 239, 244–246
  - issued at start-up, 8
  - mandatory conversion into, 82
  - valuation of, 40, 205

294 INDEX

- compounds licensing, 145–154
- confidentiality agreements, 49, 89, 131–133, 168–169, 278–281
- convertible preferred stock, 62, 64–65, 67–68, 75–79, 82, 84, 89
- copyrights, 108–109, 117–118, 174
- corporate governance, 230–235
- corporation types, 30–37
- co-sale rights, 87
- COSO (Committee of Sponsoring Organizations), 235
  
- debt covenants, 93–94
- debt financing, 90–98
- Delaware law, 6–7, 17–22, 24, 68, 271–272, 290
- demand rights, 88
- disclosure statements, 6, 185, 188, 190–197, 204–216, 218–230, 233–238
- dispute resolution, 135–136
- dividends, 27–28, 76–78, 81, 83, 93
- double-dip preferred stock, 76–77
- double taxation, 33–34, 254–256
- Dow Jones & Company, 222
- down-round financing, 58, 81
- drag-along rights, 87
- drug master file, 153–154
- due diligence, 61, 63–64, 116–121, 137–140, 151, 200, 202
- duty of care and loyalty, 28–29
  
- earnings before interest and taxes (EBIT), 274
- earnings per share (EPS), 92–93, 250
- earn-outs, 270, 274, 276–278
- EBITDA (earnings before interest, taxes, depreciation and amortization), 215
- EDGAR (electronic data gathering and retrieval) filing system, 196–197, 209, 215–218, 237, 245
- electronic filing with SEC, 196–197, 209, 215–218, 237, 245
- employee pool, 65–67
  
- employment agreements, 49–55
- end user license agreement (EULA), 126
- engineered compounds, 145–148, 153
- Enron, 206, 209, 230
- enterprise value, 92, 286
- equitable subordination, 95
- equity capitalization
  - stock issues, 7–16
- equity compensation. *See also* stock option plans
  - forms of, 9, 37–42
  - in IPOs, 37–38, 71, 73, 78, 201, 205
  - in public companies, 231, 235
  - restricted stock, 9, 37–49, 54, 75, 187, 208, 214, 243–245
  - SEC Rule 701 and, 186–189, 244, 246
  - tax aspects, 42–45
  - in venture capital deals, 69–75
- equity value, 92
- escrows, 134–135, 258, 262–264, 267–269, 286
- ethics code, 211, 213, 234–235
- exclusive license agreements, 105, 108, 114, 124, 133, 136, 145, 148–152, 155, 157–158
- exemptions from SEC registration, 182–192, 194, 214, 244–246, 270–272
  
- Federal Laboratory Consortium for Technology Transfer, 161
- fees for licensing, 126, 142, 151–152, 158, 167
- fiduciary duties, 28–30
- field of use provisions, 124–125, 145–151
- financial analysts, 221, 223–224, 226
- financial printer, 196, 209, 218
- financial statements, 92, 203, 213, 215, 225, 233
- financing, 58, 61–67, 81, 90–98. *See also* venture capital (VCs)
- first refusal rights, 10, 12, 86–87

- founders  
 corporation type and, 30–37  
 definition of, 9–10  
 due diligence investigation of, 61, 63–64  
 stock issued to, 5, 7–9, 12–18, 187  
 termination of, 2, 73  
 vesting schedules and, 39, 41
- Free Software Foundation, 140
- Gates, Bill, 1
- generally accepted accounting principles (GAAP), 92, 203, 213, 215, 233
- General Public License (GPL), 140–141, 143
- government research, 155, 157, 159–162, 164
- GPLLC (general partner limited liability company), 99–103
- grantback provisions, 147
- Hart-Scott-Rodino (HSR) Antitrust Improvements Act, 259, 262
- hazardous materials, 170
- hedge funds, 99
- holding periods, 4
- hurdle rate, 102
- IBM, 141
- incentive stock options (ISOs), 32, 34–35, 38, 43–45, 54
- incorporation, 4–6, 19–24, 30–37
- indemnification provisions  
 in clinical trials, 164  
 in licensed property, 122, 129–131, 134, 138, 176–179  
 in material transfer agreements, 169  
 in mergers and acquisitions (M&A), 258, 262–269, 288  
 in sponsored research agreements, 156
- industry research, 155–157, 160–168
- initial public offerings (IPOs). *See* IPOs (initial public offerings)
- insider loans, 206
- insider trading, 206, 208–209, 211, 220–221, 237–247
- Insider Trading and Securities Fraud Enforcement Act, 243
- insurance, 164, 171, 174. *See also* indemnification provisions
- intellectual property (IP). *See also* license agreements  
 clinical trial agreements (CTAs), 152–155, 162–164  
 confidentiality agreements, 131–133, 168–169  
 copyrights, 108–109, 117–118, 174  
 due diligence protection, 116–121  
 government research, 155, 157, 159–162, 164  
 industry research, 155–157, 160–168  
 liability limitation, 171–179  
 material transfer agreements (MTAs), 164–171  
 patents, 105–107, 116–117, 172, 175  
 sponsored research agreements, 148, 155–161  
 trademarks, 12, 20, 113–116, 119–121, 175  
 trade secrets, 109–113, 118–119, 175  
 transfer at start-up, 1–4, 11–12, 63  
 vesting and, 70
- Internal Revenue Code  
 corporation types and, 30–37  
 Section 409A, 41  
 Section 83(b), 13–14, 47–49, 74–75
- Internet bubble, 37, 81, 205
- inventions, 105–110, 116–117, 123, 149–152, 155–161, 167, 172
- investment bank engagement letters, 284–288
- investors  
 accredited, 184, 186–187, 190, 193–194  
 angel, 21, 59, 62, 75  
 rights agreements, 87  
 unaccredited, 186, 189, 191–192, 194–195

- IPOs (initial public offerings)
- accounting requirements, 202–203, 213, 215, 233
  - common stock in, 195–196, 206, 208, 210, 214, 219, 229–230, 239, 244–246
  - demand rights and, 88
  - due diligence in, 200, 202
  - equity compensation and, 37–38, 71, 73, 78, 201, 205
  - insider trading in, 206, 208–209, 211, 220–221, 237–247
  - mandatory conversion of stock, 82
  - preparatory steps, 200–206
  - press releases, 201, 213, 215, 218–219
  - registration process, 196–200
  - registration rights agreements, 88–89
  - registration statements, 196–200, 204–209
- Jobs, Steve, 1
- lawyers
- fees, 107
  - in mergers and acquisitions, 249, 253, 290–291
  - in preparing IPOs, 196–204
  - role in start-up phase, 1–4
  - in venture fund formation, 98
- legal due diligence, 61, 63–64, 116–121, 137–140, 151, 200, 202
- legends on stock certificates, 25–26
- Lehman formula, 285
- letters of intent, 281–284
- leveraged buyouts (LBOs), 91, 99
- liability, 130–131, 138, 156, 164, 169, 171–179
- license agreements
- biotechnology, 145–154
  - due diligence in, 137–140, 151
  - end user (EULA), 126
  - exclusive, 105, 108, 114, 124, 133, 136, 145, 148–152, 155, 157–158
  - fees, 126, 142, 151–152, 158, 167
  - liability limitation in, 171–179
  - milestone payments, 151–154, 162
  - nonexclusive, 124, 136, 145, 149–152, 157, 160
  - for open source software, 140–145
  - for pharmaceuticals, 146–149, 153–155, 160, 162–163
  - for software, 111, 121–139, 165, 171
- limited liability companies (LLCs), 30–37. *See also* GPLLC (general partner limited liability company)
- Linux, 141
- liquidation, 76–78, 81, 83–84, 87–88, 91, 94–98. *See also* bankruptcy
- listing standards, 236
- lock-up agreements, 198
- management companies, 100–101
- march-in rights, 160
- material adverse change (MAC), 263
- material events reports to SEC, 208–210, 212, 214, 217, 223, 225, 235, 247
- material transfer agreements (MTAs), 164–171
- MD&A (Management's Discussion and Analysis of Financial Condition and Results of Operations), 197, 203, 209–210
- mergers and acquisitions (M&A)
- accounting considerations, 259
  - acquisition agreements, 260–270
  - baskets, 265–268
  - closings, 262–263, 266, 268–269, 272–281, 286, 288, 291
  - confidentiality agreements, 278–281
  - corporate law considerations, 256–258
  - Delaware law, 271–272, 290
  - earn-outs, 270, 274, 276–278
  - investment bank engagement letters, 284–288
  - letters of intent, 281–284
  - public-to-public mergers, 288–292

- purchase price adjustments, 267, 272–275
- reasons for, 249–251
- regulatory approvals, 258–259
- securities laws aspects, 259, 270–272
- sellers terms, 267–270
- structures, 251–253
- tax considerations, 253–256
- Microsoft, 141
- milestone payments, 151–154, 162
- Nasdaq, 189, 195, 200, 204, 208, 216, 221, 230–236, 245–247
- National Association of Securities Dealers (NASD), 200
- National Institutes of Health (NIH), 161, 164–165
- National Science Foundation, 161
- National Securities Markets Improvement Act of 1976 (NSMIA), 186–187
- National Venture Capital Association (NVCA), 62
- New Hampshire, 187
- New York Stock Exchange, 195
- New York Times*, 222
- noncompetition agreements, 49, 89
- nondisclosure agreements (NDAs), 6
- nonexclusive license agreements, 124, 136, 145, 149–152, 157, 160
- nonqualified stock options (NQSOs), 38–39, 43–45, 48, 54
- “no-shop” agreements, 262–263, 282, 290
- omnibus stock plan, 40
- online filing with SEC, 196–197, 209, 215–218, 237, 245
- on-sale bar, 106
- open source software, 140–145
- Over-the Counter (OTC) Bulletin Board, 189, 206, 231
- participating preferred stock, 76–77
- patents, 105–107, 116–117, 158–159, 172, 175
- phantom stock, 41
- pharmaceuticals licensing, 146–149, 153–155, 160, 162–163
- piggyback rights, 88
- “Pink Sheets,” 206, 231
- P.L. 96–517 (Bayh-Dole Act), 167
- play-or-pay provisions, 81
- preferred stock
  - blank check, 20, 201
  - convertible, 62, 64–65, 67–68, 75–79, 82, 84, 89
  - double-dip, 76–77
  - issued to founders, 5, 7–9, 12–18, 187
  - participating, 76–77
  - pricing of, 205
  - registration of, 181
  - venture capital fund, 20–21, 40
  - veto rights, 82
- pre-money valuation, 65–67
- press releases, 201, 213, 215, 218–219, 222–226, 236
- private placements, 192–195
- prospectus, 190–191, 193–194, 196, 198–200, 203–204, 217, 228
- proxy statements, 207–209, 211, 217, 227–229, 234
- publication of results of research, 156, 159–160, 163–166, 168–169
- Public Company Accounting Oversight Board, 236
- public company regulation. *See also* Sarbanes-Oxley Act; Securities Act of 1933; Securities and Exchange Commission (SEC); Securities Exchange Act of 1934
  - corporate governance, 230–235
  - disclosure statements, 6, 185, 188, 190–197, 204–216, 218–230, 233–238
  - insider trading, 206, 208–209, 211, 220–221, 237–247
  - Nasdaq rules, 230–236
  - overview of, 207–208

- public company regulation (*Continued*)
- press releases, 218–219, 222–226, 236
  - proxy statements, 207–209, 211, 217, 227–229, 234
  - reasons to go public, 206–207
  - redemptions and repurchases, 212, 229–230, 240
  - registration statements, 214–217, 230, 239, 244, 246
  - related persons transactions, 228, 231, 234, 245
  - Securities Act of 1933 in, 206, 289–290
  - tender offers, 222, 229
  - public offerings. *See* IPOs (initial public offerings)
  - purchase price adjustments, 267, 272–275
- quarterly reports to SEC, 208, 210–212, 217, 230, 235
- redemptions and repurchases, 28, 64, 69, 73–75, 83–84, 212, 229–230, 240
- registration rights agreements, 87–89
- registration statements, 196–200, 204–209, 214–217, 230, 239, 244, 246
- related persons transactions, 228, 231, 234, 245
- remedy bars, 97
- reporting requirements (SEC), 208–226
- representations and warranties, 85–86, 122, 128–130, 159, 174, 176, 260–262
- repurchases. *See* redemptions and repurchases
- request for application (RFA), 157
- research agreements, 148, 155–161
- residuals clauses, 281
- Restatement of Torts*, 109–110
- restricted stock, 9, 37–49, 54, 75, 187, 208, 214, 243–245
- Reuters Economic Service, 222
- right of first refusal, 10, 12, 86–87
- royalties, 125–127, 142, 146, 153–154, 179
- safe harbor exemption, 183–187, 189–191, 193–194, 244, 271
- Sarbanes-Oxley Act, 48, 202–208, 230, 233–235, 247
- SCO Group, 141
- securities. *See* stocks
- Securities Act of 1933
- '33 Act Legend, 25–26
  - mandatory conversion into common stock, 82
  - public company regulation, 206, 289–290
  - Section 4(2), exemptions to SEC registration, 182–187, 189–191, 194, 271
  - Section 5, SEC registration requirement, 182
- Securities and Exchange Commission (SEC)
- EDGAR filing system, 196–197, 209, 215–218, 237, 245
  - exemptions from registration, 182–192, 194, 214, 244–246, 270–272
  - Form 144, 217, 242, 245–246
  - Form D, 184, 186–187, 189–190, 192, 195
  - Form 8-K, 208–210, 212, 214, 217, 223, 225, 235, 247
  - Form 10-K, 208–210, 216–217, 229–230, 233, 235
  - Form 10-Q, 208, 210–212, 217, 230, 235
  - Form S-1, 196–197
  - Form S-3, 88, 215
  - Forms 3, 4 and 5, 217, 229, 237–238, 241
  - Form S-4, 289
  - Form S-8, 189, 214, 216–217, 246

- registration rights of founders  
     and, 10  
 Regulation D (Reg.D), safe harbor  
     exemption, 183–187, 189–191,  
     193–194, 244, 271  
 Regulation FD, 214, 225  
 Regulation S-X, 203  
 reporting requirements, 208–226  
 Rule 144, 188, 198, 208, 214, 217,  
     243–246  
 Rule 145, 270–272  
 Rule 701, 186–189, 244, 246, 271  
 Rule 10b5–1, 242  
 Rules 501–506, 185–186  
 Sarbanes-Oxley Act, 48, 202–208,  
     230, 233–235, 247  
 Schedules 13D and 13G, 217, 239  
 Securities Exchange Act of 1934  
     in public company regulation, 206,  
     289–290  
     Regulation M, 229  
     Rule 10A-3, 232–233  
     Rule 10B-17, 216  
     Section 10(b), 182, 241  
     Section 16(b), 239–240, 246  
     Section 12(g), 189  
     short swing profit provisions, 229  
     Williams Act provisions, 229  
 self-regulatory organizations (SROs),  
     200, 204–205, 208. *See also*  
     National Association of Securities  
     Dealers (NASD)  
 service company, 21  
 service marks. *See* trademarks  
 short-swing profits, 208, 229, 238–242,  
     244, 246–247  
 side-sell analysts, 223  
 signing fees, 151–152, 158  
 software, 108–109, 111, 121–139,  
     140–145, 165, 171  
 source code escrow, 134–135  
 sponsored research agreements (SRA),  
     148, 155–161  
 statement of purpose, 20  
 stock appreciation rights (SARs), 41  
 stockholders, 17–18, 26. *See also* proxy  
     statements  
 stock option plans. *See also* cheap  
     stock; equity compensation plans  
     ISO (incentive stock options), 32,  
     34–35, 38, 43–45, 54  
     NQSO (nonqualified stock options),  
     38–39, 43–45, 48, 54  
     omnibus, 40  
     taxes on, 43–45  
 stocks. *See also* common stock;  
     preferred stock  
     appreciation rights (SARs), 41  
     authorized, 7, 20–21  
     certificates, 23, 25  
     cheap, 182, 203–205  
     dividends, 27–28, 76–78, 81, 83, 93  
     equity capitalization, 7–16  
     exchanges (*See* Nasdaq; New York  
     Stock Exchange)  
     exemptions from SEC registration,  
     182–192, 194, 214, 244–246,  
     270–272  
     issues, 5, 7–18, 23–28, 187  
     legends on certificates, 25–26  
     mandatory conversion, 82  
     options (*See* stock option plans)  
     phantom, 41  
     purchase agreements, 84–86, 199  
     record book, 25–26  
     redemptions and repurchases, 28, 64,  
     69, 73–75, 83–84, 212, 229–230,  
     240  
     related persons transactions, 228, 231,  
     234, 245  
     restricted, 9, 37–49, 54, 75, 187, 208,  
     214, 243–245  
     restriction agreements, 12–16, 70  
     sales to private placements, 192–195  
     sales to venture capital (VCs),  
     181–182, 189–192, 195  
     splits, 27, 201, 216, 222  
     subscription agreements, 23–25  
     transfers, 26  
     subchapter S corporations, 30–37

### 300 INDEX

- subordinated debt, 94–98
- subscription agreements, 23–25
- support services, 173
- sweat equity, 69
- taxes
  - capital gains, 4, 31–34, 41–43, 45
  - and corporation types, 30–37
  - double, 33–34, 254–256
  - earnings before interest and taxes (EBIT), 275
  - in mergers and acquisitions (M&A), 253–256
  - on stock options, 43–45
  - stock restriction agreements and, 13–14
- tender offers, 222, 229
- termination
  - of founders, 2, 73
- term sheets, 61–63, 65, 70
- trademarks, 12, 20, 22, 113–116, 119–121, 175
- trade secrets, 109–113, 118–119, 175
- transfer and assumption agreement, 11–12
- unaccredited investors, 186, 189, 191–192, 194–195
- underwriters, 181, 197, 199–200, 202, 246
- Uniform Biological Material Transfer Agreement (UBMTA), 164–171
- UNIX code, 141
- U.S. Customs Service, 114
- U.S. Food and Drug Administration, 107
- U.S. Patent and Trademark Office (PTO), 12, 106–107, 116
- valuation of company, 65–67
- venture capital (VCs)
  - board of directors and, 18, 67–69
  - confidentiality agreements, 89
  - convertible preferred stock, 62, 64–65, 67–68, 75–79, 82, 84, 89
  - corporation type and, 31–33
  - co-sale rights, 87
  - Delaware corporations and, 6–7, 17–22, 24, 68
  - drag-along rights, 87
  - financing, 57–59, 61–67
  - first refusal rights, 86–87
  - funds, 98–100, 102
  - GPLLC (general partner limited liability company), 99–103
  - investors' rights agreements, 87
  - legal and economic terms, 101–103
  - organizational structure and operation, 98–101
  - preferred stock and, 20–21, 40
  - registration rights agreements, 87–89
  - screening factors, 60–61
  - stock purchase agreement, 84–86, 199
  - stock sales to, 181–182, 189–192, 195
  - term sheets, 61–63, 65, 70
  - vesting and, 42, 69–75
- vesting
  - accelerated, 41–42, 71–73, 93, 97
  - agreements, 12–16
  - intellectual property (IP) and, 70
  - schedules, 39–42
  - in venture capital deals, 69–75
  - venture capital (VCs) and, 42, 69–75
- voting agreements, 68
- Wall Street Journal*, 222
- warranties, 85–86, 122, 128–130, 159, 174, 176, 260–262
- Williams Act, 229
- work-made-for-hire, 108–109
- works of authorship, 108–109
- World-Com, 206, 230